Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC.
Verra N, et al. Among authors: de gast gc, de waal m.
Br J Cancer. 2003 May 6;88(9):1346-51. doi: 10.1038/sj.bjc.6600915.
Br J Cancer. 2003.
PMID: 12778059
Free PMC article.
Clinical Trial.